SCHEMBL22200341

SCHEMBL22200341

CC(C)n1c(=O)c(-c2cc(F)c(NSCCC(F)(F)F)c(F)c2F)cc2cnc(NC3CCC(N(C)C)C(F)C3)nc21

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.46
MAPK8 P45983 10/20 0.34
MAPK10 P53779 9/20 0.34
MAPK9 P45984 8/20 0.34
BRAF P15056 1/20 0.32
CCNT1 O60563 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
CDK9 P50750 1/20 0.31
CDK6 Q00534 1/20 0.31
FGFR1 P11362 1/20 0.30
MAPK14 Q16539 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29355989 0.88 ERN1 (0.54) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL22190707 0.88 ERN1 (0.54) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL22191839 0.88 ERN1 (0.54) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL29352852 0.88 ERN1 (0.54) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL22200443 0.86 ERN1 (0.45) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL22200592 0.83 ERN1 (0.55) ERN1MAPK8MAPK10MAPK9CCNT1
SCHEMBL22200533 0.81 ERN1 (0.42) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL25035479 0.81 ERN1 (0.51) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL22200305 0.81 ERN1 (0.51) ERN1MAPK8MAPK10MAPK9BRAF
SCHEMBL22191051 0.81 ERN1 (0.51) ERN1MAPK8MAPK10MAPK9BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed